Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) EVP Charles Wagner, Jr. sold 15,286 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $547.87, for a total value of $8,374,740.82. Following the sale, the executive vice president directly owned 31,764 shares of the company’s stock, valued at $17,402,542.68. This represents a 32.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vertex Pharmaceuticals Stock Down 0.2%
Shares of NASDAQ VRTX traded down $0.81 during trading on Monday, hitting $537.79. 1,199,160 shares of the company traded hands, compared to its average volume of 1,392,167. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $412.27 and a fifty-two week high of $568.67. The firm has a market capitalization of $136.35 billion, a price-to-earnings ratio of 34.61, a P/E/G ratio of 2.85 and a beta of 0.28. The business’s fifty day moving average is $522.37 and its 200 day moving average is $483.84. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.80 EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of VRTX. BlackRock Inc. acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $11,975,849,000. State Street Corp lifted its stake in shares of Vertex Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 12,024,456 shares of the pharmaceutical company’s stock valued at $6,286,506,000 after purchasing an additional 152,997 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Vertex Pharmaceuticals by 1.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock worth $1,613,209,000 after purchasing an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Vertex Pharmaceuticals by 1.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock valued at $1,533,248,000 after acquiring an additional 29,287 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of Vertex Pharmaceuticals in the second quarter worth $1,509,651,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on VRTX. Weiss Ratings downgraded shares of Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, November 9th. Cantor Fitzgerald upped their price target on Vertex Pharmaceuticals from $595.00 to $619.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Leerink Partners assumed coverage on Vertex Pharmaceuticals in a research report on Monday, September 21st. They set an “outperform” rating and a $594.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. Finally, Evercore raised their price target on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a report on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $596.44.
View Our Latest Analysis on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
